AR119819A1 - Derivados de 1,3-fenil heteroarilo sustituidos y su uso en el tratamiento de enfermedades - Google Patents
Derivados de 1,3-fenil heteroarilo sustituidos y su uso en el tratamiento de enfermedadesInfo
- Publication number
- AR119819A1 AR119819A1 ARP200102380A ARP200102380A AR119819A1 AR 119819 A1 AR119819 A1 AR 119819A1 AR P200102380 A ARP200102380 A AR P200102380A AR P200102380 A ARP200102380 A AR P200102380A AR 119819 A1 AR119819 A1 AR 119819A1
- Authority
- AR
- Argentina
- Prior art keywords
- 4alkyl
- optionally substituted
- phenyl
- ring
- independently selected
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 27
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 11
- 229910052736 halogen Chemical group 0.000 abstract 9
- 150000002367 halogens Chemical group 0.000 abstract 9
- 125000005842 heteroatom Chemical group 0.000 abstract 9
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 abstract 4
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 150000002825 nitriles Chemical class 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 2
- -1 C2−4alkenyl Chemical group 0.000 abstract 2
- 208000025678 Ciliary Motility disease Diseases 0.000 abstract 2
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 abstract 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000009266 primary ciliary dyskinesia Diseases 0.000 abstract 2
- 101100439662 Arabidopsis thaliana CHR5 gene Proteins 0.000 abstract 1
- 206010006458 Bronchitis chronic Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010057190 Respiratory tract infections Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 201000009267 bronchiectasis Diseases 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 208000007451 chronic bronchitis Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- UCQFCFPECQILOL-UHFFFAOYSA-N diethyl hydrogen phosphate Chemical compound CCOP(O)(=O)OCC UCQFCFPECQILOL-UHFFFAOYSA-N 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 abstract 1
- 201000005296 lung carcinoma Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente se refiere a compuestos heterocíclicos de la fórmula (1) en donde todas las variables son como se definen en la memoria descriptiva, capaces de modular la actividad de TMEM16a. La presente proporciona además un método para fabricar compuestos de la presente, y sus usos terapéuticos. La misma proporciona además métodos para su preparación, para su uso médico, en particular, para su uso en el tratamiento y abordaje de enfermedades o trastornos que incluyen EPOC, bronquiectasia, asma, fibrosis quística, disquinesia ciliar primaria, bronquitis crónica, fibrosis quística, disquinesia ciliar primaria, infecciones del tracto respiratorio (aguda y crónica; viral y bacteriana), carcinoma de pulmón. Reivindicación 1: Un compuesto de fórmula (1) en donde: el anillo A es un anillo heteroarilo de 5 miembros que contiene 2 heteroátomos independientemente seleccionados de N y O; el anillo B es un anillo heteroarilo de 5 miembros que contiene 2 ó 3 heteroátomos cada uno seleccionado de manera independiente de N, S y O, en donde por lo menos uno de dichos heteroátomos es N, o el anillo B es un heteroarilo de 6 miembros que contiene 1 ó 2 heteroátomos seleccionados de N; R¹ es hidrógeno o halógeno; R² es seleccionado del grupo que consiste en: los restos del grupo de fórmulas (2) en donde R²ᵃ es H, C₁₋₄alquilo o fenilo, en donde dicho C₁₋₄alquilo está opcionalmente sustituido con halógeno, C₃₋₆cicloalquilo, fenilo, -O-C₁₋₄alquilo o -S-C₁₋₄alquilo; R²ᵇ es H, C₁₋₄alquilo, o R²ᵇ tomado junto con R²ᵃ forma un anillo C₃₋₆cicloalquilo; R²ᶜ es C₁₋₄alquilo, C₂₋₄alquenilo o bencilo; R²ᵈ es C₁₋₄alquilo, C₃₋₆cicloalquilo, adamantilo, un heteroarilo de 5 ó 6 miembros en donde dicho heteroarilo contiene 1 ó 2 heteroátomos independientemente seleccionados de N y O, o fenilo; en donde dicho fenilo está opcionalmente sustituido con 1 ó 2 sustituyentes independientemente seleccionados de C₁₋₄alquilo, halo-C₁₋₄alquilo y nitrilo; R²ᵉ es H, C₁₋₄alquilo o anillo C₃₋₆cicloalquilo; R²ᶠ es H, C₁₋₄alquilo o anillo C₃₋₆cicloalquilo opcionalmente sustituido con C₁₋₄alquilo, o R²ᵉ tomado junto con R²ᶠ forma un anillo C₃₋₆cicloalquilo; R²ᵍ es H, C₁₋₄alquilo, un resto fusionado seleccionado de benzo[d][1,3]dioxol e indolin-2-ona, donde dicho resto fusionado está opcionalmente sustituido con halógeno o C₁₋₄alquilo, C₃₋₆heterocicloalquilo que contiene 1 ó 2 heteroátomos seleccionados de N y O, -C₀₋₂alquilo-fenilo en donde dicho fenilo está opcionalmente sustituido 1 ó 2 grupos independientemente seleccionados de halógeno y C₁₋₄alquilo; R³ es H, C₁₋₅alquilo o un heterociclo saturado de 4 a 6 miembros que contiene O; en donde dicho C₁₋₅alquilo está opcionalmente sustituido con 1 a 3 grupos independientemente seleccionados de hidroxilo, C₁₋₅alcoxi, halógeno, dietil fosfato, -C(O)OC₁₋₄alquilo, NH-bencilo, O-bencilo, benzo[d][1,3]dioxol, isoindolinilo, -O-C₂₋₄alquilo-O-C₁₋₄alquilo, y un heterociclo saturado de 4 a 6 miembros que contiene 1 ó 2 heteroátomos seleccionados de N y O en donde dicho heterociclo está opcionalmente sustituido con 1 ó 2 grupos seleccionados de C₁₋₄alquilo, y -C(O)NH(CHR⁵)C(O)O-C₁₋₄alquilo; R⁴ es seleccionado del grupo que consiste en: los restos del grupo de fórmulas (3) donde R⁴ᵃ es H, C₁₋₄alquilo o fenilo, en donde dicho C₁₋₄alquilo está opcionalmente sustituido con 1 a 3 halógenos, C₃₋₆cicloalquilo, fenilo, -O-C₁₋₄alquilo o -S-C₁₋₄alquilo; R⁴ᵇ es H o C₁₋₄alquilo, o R⁴ᵇ es tomado junto con R⁴ᵃ para formar un anillo C₃₋₆cicloalquilo; R⁴ᶜ es C₁₋₄alquilo, C₂₋₄alquenilo o bencilo; R⁴ᵉ es H, C₁₋₄alquilo, C₁₋₄alcoxi o anillo C₃₋₆cicloalquilo; R⁴ᶠ es H, C₁₋₄alquilo o anillo C₃₋₆cicloalquilo opcionalmente sustituido con nitrilo o C₁₋₄alquilo, o R⁴ᵉ es tomado junto con R⁴ᶠ para formar un anillo C₃₋₆cicloalquilo; R⁴ᵍ es H, C₁₋₄alquilo, un resto fusionado seleccionado de benzo[d][1,3]dioxol e indolin-2-ona, donde dicho resto fusionado está opcionalmente sustituido con halógeno o C₁₋₄alquilo, C₃₋₆heterocicloalquilo que contiene 1 ó 2 heteroátomos seleccionados de N y O, -C₀₋₂alquilo-fenilo en donde dicho fenilo está opcionalmente sustituido con 1 ó 2 halógenos; R⁴ʰ es C₁₋₄alquilo, C₃₋₆cicloalquilo opcionalmente sustituido con 1 ó 2 halógenos, adamantilo, heteroarilo de 5 ó 6 miembros en donde dicho heteroarilo contiene 1 ó 2 heteroátomos independientemente seleccionados de N y O, fenilo; en donde dicho fenilo es opcionalmente sustituido con 1 ó 2 sustituyentes independientemente seleccionados de C₁₋₄alquilo, C₁₋₅alcoxi, halo-C₁₋₄alquilo, halo-C₁₋₄alcoxi y nitrilo; R⁴ⁱ es H, o R⁴ⁱ tomado junto con R⁴ʰ forma un anillo C₃₋₆heterocicloalquilo opcionalmente sustituido con 1 ó 2 sustituyentes independientemente seleccionados de C₁₋₄alquilo, C₁₋₄alcoxi y -C(O)OC₁₋₄alquilo; y R⁵ es H o C₁₋₄alquilo, en donde dicho C₁₋₄alquilo está opcionalmente sustituido con C₃₋₆cicloalquilo, fenilo, -O-C₁₋₄alquilo o -S-C₁₋₄alquilo; o una de sus sales, hidratos o cocristales farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962892664P | 2019-08-28 | 2019-08-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR119819A1 true AR119819A1 (es) | 2022-01-12 |
Family
ID=72292591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200102380A AR119819A1 (es) | 2019-08-28 | 2020-08-24 | Derivados de 1,3-fenil heteroarilo sustituidos y su uso en el tratamiento de enfermedades |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20220306617A1 (es) |
| EP (1) | EP4021572A1 (es) |
| JP (1) | JP2022547427A (es) |
| KR (1) | KR20220052934A (es) |
| CN (1) | CN114341132A (es) |
| AR (1) | AR119819A1 (es) |
| AU (1) | AU2020338971B2 (es) |
| BR (1) | BR112022002569A2 (es) |
| CA (1) | CA3146109A1 (es) |
| CO (1) | CO2022001387A2 (es) |
| CR (1) | CR20220060A (es) |
| DO (1) | DOP2022000034A (es) |
| EC (1) | ECSP22011156A (es) |
| IL (1) | IL289616A (es) |
| JO (1) | JOP20220044A1 (es) |
| MX (1) | MX2022002374A (es) |
| PE (1) | PE20220346A1 (es) |
| TW (1) | TWI753550B (es) |
| UY (1) | UY38860A (es) |
| WO (1) | WO2021038426A1 (es) |
Family Cites Families (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1219606A (en) | 1968-07-15 | 1971-01-20 | Rech S Et D Applic Scient Soge | Quinuclidinol derivatives and preparation thereof |
| JPS6235216A (ja) | 1985-08-09 | 1987-02-16 | Noritoshi Nakabachi | 不均質物質層の層厚非破壊測定方法および装置 |
| GB8923590D0 (en) | 1989-10-19 | 1989-12-06 | Pfizer Ltd | Antimuscarinic bronchodilators |
| PT100441A (pt) | 1991-05-02 | 1993-09-30 | Smithkline Beecham Corp | Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso |
| WO1993018007A1 (en) | 1992-03-13 | 1993-09-16 | Tokyo Tanabe Company Limited | Novel carbostyril derivative |
| WO1993019750A1 (en) | 1992-04-02 | 1993-10-14 | Smithkline Beecham Corporation | Compounds useful for treating allergic or inflammatory diseases |
| US5605923A (en) | 1992-04-02 | 1997-02-25 | Smithkline Beecham Corporation | Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor |
| US5552438A (en) | 1992-04-02 | 1996-09-03 | Smithkline Beecham Corporation | Compounds useful for treating allergic and inflammatory diseases |
| GB9622386D0 (en) | 1996-10-28 | 1997-01-08 | Sandoz Ltd | Organic compounds |
| US6166037A (en) | 1997-08-28 | 2000-12-26 | Merck & Co., Inc. | Pyrrolidine and piperidine modulators of chemokine receptor activity |
| AU9281298A (en) | 1997-10-01 | 1999-04-23 | Kyowa Hakko Kogyo Co. Ltd. | Benzodioxole derivatives |
| US6362371B1 (en) | 1998-06-08 | 2002-03-26 | Advanced Medicine, Inc. | β2- adrenergic receptor agonists |
| BR9815931A (pt) | 1998-06-30 | 2001-02-20 | Dow Chemical Co | Polióis poliméricos, um processo para sua produção, e espuma de poliuretanoobtida |
| GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| HUP0203528A3 (en) | 1999-05-04 | 2003-11-28 | Schering Corp | Piperidine derivatives useful as ccr5 antagonists, pharmaceutical compositions containing them and their use |
| KR100439358B1 (ko) | 1999-05-04 | 2004-07-07 | 쉐링 코포레이션 | Ｃｃｒ5 길항제로서 유용한 피페라진 유도체 |
| US6683115B2 (en) | 1999-06-02 | 2004-01-27 | Theravance, Inc. | β2-adrenergic receptor agonists |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| EA006685B1 (ru) | 1999-08-21 | 2006-02-24 | Алтана Фарма Аг | Синергетическая композиция |
| OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
| HUP0300832A2 (hu) | 2000-04-27 | 2003-08-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Új, lassú hatású bétamimetikumok, eljárás előállításukra és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények |
| ES2213703T5 (es) | 2000-06-27 | 2011-11-02 | Laboratorios S.A.L.V.A.T., S.A. | Carbamatos derivados de arilalquilaminas. |
| GB0015876D0 (en) | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
| DE10038639A1 (de) | 2000-07-28 | 2002-02-21 | Schering Ag | Nichtsteroidale Entzündungshemmer |
| WO2002012265A1 (en) | 2000-08-05 | 2002-02-14 | Glaxo Group Limited | 6.ALPHA., 9.ALPHA.-DIFLUORO-17.ALPHA.-`(2-FURANYLCARBOXYL) OXY!-11.BETA.-HYDROXY-16.ALPHA.-METHYL-3-OXO-ANDROST-1,4,-DIENE-17-CARBOTHIOIC ACID S-FLUOROMETHYL ESTER AS AN ANTI-INFLAMMATORY AGENT |
| GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| EP1345937B1 (en) | 2000-12-22 | 2005-09-28 | Almirall Prodesfarma AG | Quinuclidine carbamate derivatives and their use as m3 antagonists |
| ES2266291T3 (es) | 2000-12-28 | 2007-03-01 | Almirall Prodesfarma Ag | Nuevos derivados de quinuclidina y composiciones medicinales que los contienen. |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| US7144908B2 (en) | 2001-03-08 | 2006-12-05 | Glaxo Group Limited | Agonists of beta-adrenoceptors |
| ATE381537T1 (de) | 2001-03-22 | 2008-01-15 | Glaxo Group Ltd | Formanilid-derivative als beta2-adrenorezeptor- agonisten |
| SI1383786T1 (sl) | 2001-04-30 | 2009-02-28 | Glaxo Group Ltd | Protivnetni 17.beta-karbotioatestrski derivati androstana s ciklično estrsko skupino na položaju 17.alfa |
| ES2307751T3 (es) | 2001-06-12 | 2008-12-01 | Glaxo Group Limited | Nuevos esteres heterociclicos centi-inflamatorios 17 alfa de derivados 17 beta de carbotioato de androstano. |
| EP2327765B1 (en) | 2001-06-21 | 2015-04-01 | BASF Enzymes LLC | Nitrilases |
| PL393155A1 (pl) | 2001-09-14 | 2011-03-28 | Glaxo Group Limited | Pochodne fenetanoloaminy do leczenia chorób układu oddechowego |
| US7361668B2 (en) | 2001-10-17 | 2008-04-22 | Ucb, S.A. | Quinuclidine derivatives processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors |
| GB0125259D0 (en) | 2001-10-20 | 2001-12-12 | Glaxo Group Ltd | Novel compounds |
| AR037517A1 (es) | 2001-11-05 | 2004-11-17 | Novartis Ag | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria |
| TWI249515B (en) | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
| US6653323B2 (en) | 2001-11-13 | 2003-11-25 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
| AU2002356759A1 (en) | 2001-12-01 | 2003-06-17 | Glaxo Group Limited | 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents |
| CN1832948B (zh) | 2001-12-20 | 2011-06-15 | 基耶西药品股份公司 | 1-烷基-1-氮*双环[2.2.2]辛烷氨基甲酸酯衍生物及其用作蕈毒碱受体拮抗剂的用途 |
| WO2003072592A1 (en) | 2002-01-15 | 2003-09-04 | Glaxo Group Limited | 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents |
| WO2003062259A2 (en) | 2002-01-21 | 2003-07-31 | Glaxo Group Limited | Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents |
| GB0202216D0 (en) | 2002-01-31 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
| GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
| WO2003082787A1 (en) | 2002-03-26 | 2003-10-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| ES2298508T3 (es) | 2002-03-26 | 2008-05-16 | Boehringer Ingelheim Pharmaceuticals Inc. | Mimeticos de glucocorticoides, metodos para prepararlos, composiciones farmaceuticas y sus usos. |
| DE60335869D1 (de) | 2002-04-11 | 2011-03-10 | Merck Sharp & Dohme | 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren |
| ES2206021B1 (es) | 2002-04-16 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de pirrolidinio. |
| ES2298511T3 (es) | 2002-04-25 | 2008-05-16 | Glaxo Group Limited | Derivados de fenetanolamina. |
| EP1507754A1 (en) | 2002-05-28 | 2005-02-23 | Theravance, Inc. | Alkoxy aryl beta-2 adrenergic receptor agonists |
| US7186864B2 (en) | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| ES2201907B1 (es) | 2002-05-29 | 2005-06-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de indolilpiperidina como potentes agentes antihistaminicos y antialergicos. |
| DE10224888A1 (de) | 2002-06-05 | 2003-12-24 | Merck Patent Gmbh | Pyridazinderivate |
| US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| DE10225574A1 (de) | 2002-06-10 | 2003-12-18 | Merck Patent Gmbh | Aryloxime |
| DE10227269A1 (de) | 2002-06-19 | 2004-01-08 | Merck Patent Gmbh | Thiazolderivate |
| DE60312520T2 (de) | 2002-06-25 | 2007-11-22 | Merck Frosst Canada Ltd., Kirkland | 8-(biaryl)chinolin-pde4-inhibitoren |
| ES2204295B1 (es) | 2002-07-02 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de quinuclidina-amida. |
| WO2004005258A1 (en) | 2002-07-02 | 2004-01-15 | Merck Frosst Canada & Co. | Di-aryl-substituted-ethane pyridone pde4 inhibitors |
| PT1521733E (pt) | 2002-07-08 | 2014-10-29 | Pfizer Prod Inc | Moduladores do recetor de glucocorticoides |
| GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| AR040962A1 (es) | 2002-08-09 | 2005-04-27 | Novartis Ag | Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto |
| CA2494643A1 (en) | 2002-08-10 | 2004-03-04 | Altana Pharma Ag | Piperidine-n-oxide-derivatives |
| AU2003255376A1 (en) | 2002-08-10 | 2004-03-11 | Altana Pharma Ag | Piperidine-derivatives as pde4 inhibitors |
| JP4555684B2 (ja) | 2002-08-10 | 2010-10-06 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｐｄｅ４阻害剤としての、ピロリジンジオンにより置換されたピペリジン−フタラゾン |
| US20060167001A1 (en) | 2002-08-10 | 2006-07-27 | Sterk Jan G | Pyridazinone-derivatives as pde4 inhibitors |
| PL373598A1 (en) | 2002-08-17 | 2005-09-05 | Altana Pharma Ag | Novel benzonaphthyridines |
| US20060116518A1 (en) | 2002-08-17 | 2006-06-01 | Altana Pharma Ag | Novel phenanthridines |
| SE0202483D0 (sv) | 2002-08-21 | 2002-08-21 | Astrazeneca Ab | Chemical compounds |
| EP1532113B1 (en) | 2002-08-21 | 2008-08-06 | Boehringer Ingelheim Pharmaceuticals Inc. | Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| EP1534675B1 (en) | 2002-08-23 | 2009-02-25 | Ranbaxy Laboratories, Ltd. | Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo¬3.1.0 hexane derivatives as muscarinic receptor antagonists |
| KR20050036982A (ko) | 2002-08-29 | 2005-04-20 | 베링거 인겔하임 파마슈티칼즈, 인코포레이티드 | 염증, 알러지 및 증식성 질환의 치료에 글루코코르티코이드모사체로 사용하기 위한 3-(설폰아미도에틸)-인돌 유도체 |
| ES2281658T3 (es) | 2002-08-29 | 2007-10-01 | Nycomed Gmbh | 3-hidroxi-6-fenilfenantridinas como inhibidores de pde-4. |
| WO2004019944A1 (en) | 2002-08-29 | 2004-03-11 | Altana Pharma Ag | 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors |
| GB0220730D0 (en) | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
| CN1688577A (zh) | 2002-09-18 | 2005-10-26 | 小野药品工业株式会社 | 三氮杂螺[5.5]十一烷衍生物及以它为活性成分的药物 |
| JP2006096662A (ja) | 2002-09-18 | 2006-04-13 | Sumitomo Pharmaceut Co Ltd | 新規６−置換ウラシル誘導体及びアレルギー性疾患の治療剤 |
| JP2004107299A (ja) | 2002-09-20 | 2004-04-08 | Japan Energy Corp | 新規１−置換ウラシル誘導体及びアレルギー性疾患の治療剤 |
| WO2004026248A2 (en) | 2002-09-20 | 2004-04-01 | Merck & Co., Inc. | Octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators |
| DE10246374A1 (de) | 2002-10-04 | 2004-04-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| KR20050047552A (ko) | 2002-10-11 | 2005-05-20 | 화이자 인코포레이티드 | 베타-2 작용제로서의 인돌 유도체 |
| EP1440966A1 (en) | 2003-01-10 | 2004-07-28 | Pfizer Limited | Indole derivatives useful for the treatment of diseases |
| US20060205790A1 (en) | 2002-10-22 | 2006-09-14 | Coe Diane M | Medicinal arylethanolamine compounds |
| EP1554262B1 (en) | 2002-10-23 | 2007-12-05 | Glenmark Pharmaceuticals Limited | Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
| PL377122A1 (pl) | 2002-10-28 | 2006-01-23 | Glaxo Group Limited | Pochodne fenetanoloaminy do leczenia chorób układu oddechowego |
| GB0225030D0 (en) | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
| GB0225287D0 (en) | 2002-10-30 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| DE10253282A1 (de) | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung |
| DE10253426B4 (de) | 2002-11-15 | 2005-09-22 | Elbion Ag | Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung |
| DE10253220A1 (de) | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| DE10261874A1 (de) | 2002-12-20 | 2004-07-08 | Schering Ag | Nichtsteroidale Entzündungshemmer |
| AU2004207482B2 (en) | 2003-01-21 | 2009-10-08 | Merck Sharp & Dohme Corp. | 17-carbamoyloxy cortisol derivatives as selective glucocorticoid receptor modulators |
| PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| EP1460064A1 (en) | 2003-03-14 | 2004-09-22 | Pfizer Limited | Indole-2-carboxamide derivatives useful as beta-2 agonists |
| GB0312832D0 (en) | 2003-06-04 | 2003-07-09 | Pfizer Ltd | 2-amino-pyridine derivatives useful for the treatment of diseases |
| CA2528851A1 (en) | 2003-06-10 | 2004-12-16 | Ace Biosciences A/S | Extracellular aspergillus polypeptides |
| JP2010529079A (ja) | 2007-06-06 | 2010-08-26 | ノバルティス アーゲー | 抗炎症性置換シクロブテンジオン化合物 |
| US9790218B2 (en) * | 2011-08-05 | 2017-10-17 | The Regents Of The University Of California | Small molecule activators of calcium-activated chloride channels and methods of use |
| EP3157917B1 (en) * | 2014-06-19 | 2020-03-18 | Proteostasis Therapeutics, Inc. | Compounds, compositions and methods of increasing cftr activity |
-
2020
- 2020-08-24 KR KR1020227006043A patent/KR20220052934A/ko unknown
- 2020-08-24 US US17/638,106 patent/US20220306617A1/en active Pending
- 2020-08-24 CA CA3146109A patent/CA3146109A1/en active Pending
- 2020-08-24 JO JOP/2022/0044A patent/JOP20220044A1/ar unknown
- 2020-08-24 CR CR20220060A patent/CR20220060A/es unknown
- 2020-08-24 CN CN202080059610.2A patent/CN114341132A/zh active Pending
- 2020-08-24 BR BR112022002569A patent/BR112022002569A2/pt unknown
- 2020-08-24 JP JP2022513293A patent/JP2022547427A/ja active Pending
- 2020-08-24 EP EP20764788.4A patent/EP4021572A1/en active Pending
- 2020-08-24 AR ARP200102380A patent/AR119819A1/es unknown
- 2020-08-24 MX MX2022002374A patent/MX2022002374A/es unknown
- 2020-08-24 WO PCT/IB2020/057905 patent/WO2021038426A1/en active Application Filing
- 2020-08-24 UY UY0001038860A patent/UY38860A/es unknown
- 2020-08-24 AU AU2020338971A patent/AU2020338971B2/en not_active Expired - Fee Related
- 2020-08-24 PE PE2022000246A patent/PE20220346A1/es unknown
- 2020-08-26 TW TW109129135A patent/TWI753550B/zh active
-
2022
- 2022-01-04 IL IL289616A patent/IL289616A/en unknown
- 2022-02-10 DO DO2022000034A patent/DOP2022000034A/es unknown
- 2022-02-11 CO CONC2022/0001387A patent/CO2022001387A2/es unknown
- 2022-02-11 EC ECSENADI202211156A patent/ECSP22011156A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022547427A (ja) | 2022-11-14 |
| ECSP22011156A (es) | 2022-03-31 |
| BR112022002569A2 (pt) | 2022-07-19 |
| PE20220346A1 (es) | 2022-03-14 |
| CO2022001387A2 (es) | 2022-03-18 |
| CA3146109A1 (en) | 2021-03-04 |
| DOP2022000034A (es) | 2022-03-15 |
| JOP20220044A1 (ar) | 2023-01-30 |
| US20220306617A1 (en) | 2022-09-29 |
| EP4021572A1 (en) | 2022-07-06 |
| TW202122386A (zh) | 2021-06-16 |
| WO2021038426A1 (en) | 2021-03-04 |
| AU2020338971A1 (en) | 2022-01-27 |
| MX2022002374A (es) | 2022-03-29 |
| UY38860A (es) | 2021-02-26 |
| AU2020338971B2 (en) | 2023-11-23 |
| CN114341132A (zh) | 2022-04-12 |
| IL289616A (en) | 2022-03-01 |
| CR20220060A (es) | 2022-03-01 |
| KR20220052934A (ko) | 2022-04-28 |
| TWI753550B (zh) | 2022-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020009225A2 (es) | Análogos de dihidrobenzofurano e indeno como inhibidores del sarcómero cardíaco | |
| AR108325A1 (es) | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas | |
| EA201992884A3 (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| AR045595A1 (es) | Composiciones utiles como inhibidores de proteinas quinasas | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| AR109437A1 (es) | Derivados de n-(piridin-2-il)piridina-sulfonamida y su uso en el tratamiento de enfermedades | |
| AR111314A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| AR103064A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
| AR057131A1 (es) | Derivados de purina como inmunomodulador | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| AR116283A1 (es) | Inhibidores del sarcómero cardíaco | |
| AR119234A1 (es) | Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades | |
| AR093937A1 (es) | Compuestos quimicos | |
| AR111808A1 (es) | Derivados de pirimidina como moduladores del receptor de pge2 | |
| CO2021002976A2 (es) | Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak | |
| AR111494A1 (es) | Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer | |
| AR119244A1 (es) | Derivados de 2h-indazol y su uso en el tratamiento de enfermedades | |
| AR119322A1 (es) | Compuestos derivados de 1h-pirido[1,2-a]pirazina como inhibidores de magl | |
| EA202191968A1 (ru) | Новые замещенные производные сульфонилмочевины | |
| AR124451A1 (es) | DERIVADOS DE IMIDAZO[1,2-a]PIRIDINILO Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES | |
| AR119819A1 (es) | Derivados de 1,3-fenil heteroarilo sustituidos y su uso en el tratamiento de enfermedades | |
| AR123049A1 (es) | Compuestos terapéuticos y modos de uso | |
| AR120169A1 (es) | Derivados de 2-azaespiro[3.4]octano como agonistas de m4 | |
| PE20211454A1 (es) | Derivados de imidazopiridina y su uso como medicamento | |
| AR126048A1 (es) | Derivados heterocíclicos condensados |